XSpray Pharma AB, a Swedish biotechnology company, specializes in particle manufacturing and solid-state characterization services, particularly in protein kinase inhibitors, and has a significant market presence with a market capitalization of 1.95…

XSpray Pharma AB completed a fully subscribed rights issue, raising a total of SEK 161 million to support its research and development activities and strengthen its balance sheet.

XSpray Pharma AB is a prominent biotechnology company specializing in particle manufacturing and solid-state characterization services, with a strong focus on protein kinase inhibitors and a significant presence in the health care industry.